诺诚健华医药有限公司（“诺诚健华”）近日在上海证券交易所科创板上市，募资约29.19亿元。方达律师事务所担任发行人律师，嘉源律师事务所则为保荐人中金公司提供法律意见。

诺诚健华成立于2015年，总部位于中国香港，是一家创新生物医药企业，专注于肿瘤和自身免疫性疾病等领域的药物研发。2020年，诺诚健华在香港上市。

方达团队由合伙人丁继栋、刘一苇律师牵头，嘉源团队的经办律师则为合伙人傅扬远、刘静、钟云长律师。

Fangda and Jia Yuan acted on InnoCare Pharma’s listing on STAR Market

Fangda Partners has advised the Hong Kong based and listed medicine maker InnoCare Pharma’s $414 million listing on Shanghai’s STAR Market, with Jia Yuan Law Offices advising the sponsor CICC.

Established in 2015, InnoCare is an enterprise focusing on the development of biological medicine treating tumour and autoimmune diseases. In 2020, the company finished its IPO in Hong Kong SAR.

The Fangda team was led by partners Jeffrey Ding and Yvette Liu, while the Jia Yuan team was led by partners Fu Yangyuan, Liu Jing, and Zhong Yunchang.